Cytodyn Inc (CYDY)

[Leronlimab4DaWin]

Manuscript Findings


1) There is nothing to do here bc it isn;t a controlled trial
2) It is only 23 patients
3) "Routine inflammatory and cell prognostic markers did not markedly change immediately after treatment"
4) Mortality rates at 17% were higher than both Remdesivir severe-to-critical and placebo in Gilead's most recent trial (below), which were 15% and 13%, respectively. Only 1 patient got Remdesivir in this trial

Redemsivir Trial

5) That is a long list of conflicts of interest
6) Where is the CD10 manuscript? This is taking a very long time